This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Mechanism

Authoring team

DUB may be due to an alteration in the output, or balance, of gonadotrophic or ovarian hormones, and/or an endometrial defect in the secretion or release of prostaglandins. In most cases, cycles are anovulatory.

Immediately after puberty and near to the menopause, DUB is frequently attributed to an inadequate ovarian response to FSH. The endometrium is inadequately stimulated on account of the reduced production of oestrogen, producing irregular bleeding.

In other cases, oestrogen production is prolonged resulting in cystic hyperplasia of the endometrium, a syndrome known as "metropathia haemorrhagica." The basis is absence of feedback inhibition of pituitary FSH secretion. Amenorrhoea occurs initially but after 6-8 weeks, is followed by excessive endometrial shedding as oestrogen levels fall.

DUB may also occur because of increased production of prostacyclin - PGI2 - and / or PGE2, with a relative decrease in PGF2-alpha. These prostaglandins are synthesised by the endometrium and myometrium from arachidonic acid. Their effects are:

  • PGI2 - myometrial relaxation and vasodilation; platelet inhibition
  • PGE2 - mymoetrial contraction and vasodilation
  • PGF2-alpha - myometrial contraction and vasoconstriction

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.